Tolterodine: pharmokinetics, efficacy and safety

References

• Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn.23(3), 280–281 (2004).
   Google Scholar
• Homma Y, Yamaguchi O, Hayashi K. Neurogenic Bladder Society Meeting. An epidemiological survey of overactive bladder symptoms in Japan. BJU Int.96(9), 1314–1318 (2005).
   PubMed Web of Science ®Google Scholar
• Nygaard IE, Lemke JH. Urinary incontinence in rural older women: prevalence, incidence, and remission. J. Am. Geriatr. Soc.44(9), 1049–1054 (1996).
   PubMed Web of Science ®Google Scholar
• Teloken C, Caraver F, Weber FA et al. Overactive bladder: prevalence and implications in Brazil. Eur. Urol.49, 1087–1092 (2006).
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen, Cundiff GW et al. Prevalence of overactive bladder in the United States. World J. Urol.20, 327–336 (2003).
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am. J. Manag. Care6(11Suppl.), S580–S590 (2000).
   PubMed Web of Science ®Google Scholar
• Hu T, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology63, 461–465 (2004).
   PubMed Web of Science ®Google Scholar
• Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy24(4), 511–519 (2005).
   Google Scholar
• Chancellor MB, Yoshimura N. Neurophysiology of stress urinary incontinence. Rev. Urol.6(Suppl. 3), S19–S28 (2004).
   Google Scholar
• Chu FM, Dmochowski R. Pathophysiology of overactive bladder. Am. J. Med.119(3a), S3–S8 (2006).
   PubMed Web of Science ®Google Scholar
• Hegde SS, Eglen RM. Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci.64, 419–428 (1999).
   PubMed Web of Science ®Google Scholar
• Fetscher C, Fleichman M, Schmidt M, Krege S, Michel MC. M3 muscarinic receptors mediate contraction of human urinary bladder. Br. J. Pharmacol.136, 641–643 (2002).
   PubMed Web of Science ®Google Scholar
• Kumar V, Cross RL, Chess-Williams R, Chapple CR. Recent advances in basic science for overactive bladder. Curr. Opin. Urol.15, 222–226 (2005).
   PubMed Web of Science ®Google Scholar
• Burgio K. Behavioral treatment options for urinary incontinence. Gatroenterology126(1 Suppl. 1), S82–S89 (2004).
   PubMed Web of Science ®Google Scholar
• Ostaszkiewicz J, Roe B, Johnston L. Effects of timed voiding in the management of urinary incontinence in adults: a systematic review. J. Adv. Nurs.52(4), 420–431 (2005).
   Google Scholar
• Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge inconitinence in older women. J. Am. Geriatr. Soc.48(4), 370–374 (2000).
   PubMed Web of Science ®Google Scholar
• Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet. Gynecol.95(5), 718–721 (2000).
   PubMed Web of Science ®Google Scholar
• Swift S, Garely A, Dimpfl T, Payne C. A new once daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. Int. Urogynecol. J.12, 50–55 (2003).
   Google Scholar
• Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter Phase III trial studying trospium chloride in patients with overactive bladder. Urology67(2), 275–280 (2006).
   PubMed Web of Science ®Google Scholar
• Napier C, Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype. Neurourol Urodyn.21, A445 (2002).
   Google Scholar
• Siegel S, Catanzaro F, Dijkema H et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology56(6 Suppl. 1), S87–S91 (2000).
   PubMed Web of Science ®Google Scholar
• Rapp DE, Lucioni A, Katz EE, O’Connor RC, Gerber GS, Bales GT. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urology63, 1071–1075 (2004).
   PubMedGoogle Scholar
• Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Tolterodine – a new bladder-selective antimuscarinic agent. Eur. J. Pharmacol.327, 195–207 (1997).
   PubMed Web of Science ®Google Scholar
• Guay DRP. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin. Pharmacokinet.42(14), 1243–1285 (2003).
   PubMed Web of Science ®Google Scholar
• Brynne N, Dalen P, Alvan G, Bertilsson L, Gabrielsson J. Influence of CYP2DP polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine. Clin. Pharmacol. Ther.63, 529–539 (1998).
   PubMed Web of Science ®Google Scholar
• Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin. Pharmacokinet.40(3), 227–235 (2001).
   PubMed Web of Science ®Google Scholar
• Colucci VJ, Rivey MP. Tolterodine–warfarin drug interaction. Ann. Pharmacother.33, 1173–1176 (1999).
   PubMed Web of Science ®Google Scholar
• Rahimy M, Hallen B, Narang P. Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers. Arzneimittelforschung52(12), 890–895 (2002).
   PubMed Web of Science ®Google Scholar
• Sathyan G, Dmochowski RR, Appell RA, Guo C, Gupta SK. Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin. Clin. Pharmacokinet.43(14), 1059–1068 (2004).
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Chen A, Sathyan G, MacDiarmid S, Gidwani S, Gupta S. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. J. Clin. Pharmacol.45, 961–968 (2005).
   PubMed Web of Science ®Google Scholar
• Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in aging. Br. J. Pharmacol.144(8), 1089–1099 (2005).
   PubMed Web of Science ®Google Scholar
• Chapple C, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology60(5 Suppl. 1), S82–S88 (2002).
   Google Scholar
• Somogyi GT, Tanowitz M, de Groat WC. Evidence for nicotinic and facilitatory muscarinic receptors in cholinergic nerve terminals of the rat urinary bladder. Auton. Nerv. Syst.37, 89–98 (1992).
   PubMedGoogle Scholar
• Somogyi GT, Tanowitz M, de Groat WC. M1 muscarinic receptor-mediated facilitation of acetycholine release in the rat urinary bladder. J. Physiol.140, 81–89 (1994).
   Google Scholar
• Nilvebrant L. Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. Pharmacol. Toxicol.90, 260–267 (2002).
   PubMedGoogle Scholar
• Kim Y, Yoshimura N, Masuda H et al. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology65, 238–242 (2005).
   PubMed Web of Science ®Google Scholar
• Yokoyama O, Yusup A, Miwa Y, Oyama N, Aoki Y, Akino H. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J. Urol.174, 2032–2036 (2005).
   PubMed Web of Science ®Google Scholar
• Gillberg P, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype selective muscarinic receptor antagonists. Eur. J. Pharmacol.349, 285–292 (1998).
   PubMed Web of Science ®Google Scholar
• Nilvebrant L. The mechanism of action of tolterodine. Rev. Contemp. Pharmacother.11, 13–27 (2000).
   Web of Science ®Google Scholar
• Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J. Clin. Pharmacol.41, 636–644 (2001).
   PubMed Web of Science ®Google Scholar
• Kang J, Chen XL, Wang H et al. Cardiac ion channel effects of tolterodine. J. Pharmacol. Exp. Ther.308, 935–940 (2003).
   Google Scholar
• Larsson G, Hallen B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: analysis of the pooled Phase II efficacy and safety data. Urology53, 990–998 (1999).
   PubMed Web of Science ®Google Scholar
• Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology50, 90–96 (1997).
   PubMed Web of Science ®Google Scholar
• Appell RA, Abrams P, Drutz HP, Van Kerrebroek PE, Millard R, Wein A. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J. Urol.19, 141–147 (2001).
   PubMed Web of Science ®Google Scholar
• Stamey TA. Endoscopic suspension of the vesical neck for urinary incontinence. Surg. Gynecol. Obstet.136, 547 (1973).
   PubMedGoogle Scholar
• Michel MC, de la Rosette JJMCH, Piro M, Goepel M. Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder? J. Urol.172, 601–604 (2004).
   PubMedGoogle Scholar
• Harvey M, Baker K, Wells G. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am. J. Obstet. Gynecol.185, 56–61 (2001).
   PubMed Web of Science ®Google Scholar
• Appell RA, Sand P, Dmochowski R et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results form the OBJECT study. Mayo Clin. Proc.76, 358–363 (2001).
   PubMed Web of Science ®Google Scholar
• Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology57, 414–421 (2001).
   PubMed Web of Science ®Google Scholar
• Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine I the treatment of overactive bladder. Eur. Urol.41, 588–595 (2002).
   PubMed Web of Science ®Google Scholar
• Diokno AC, Appell RA, Sand PK et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin. Proc.78, 687–695 (2003).
   PubMed Web of Science ®Google Scholar
• Khullar V, Hill S, Laval K, Schiotz HA, Jonas U, Versi E. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology64, 269–275 (2004).
   PubMed Web of Science ®Google Scholar
• Chapple CR, Martinez-Garcia R, Selvaggi L et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur. Urol.48, 464–470 (2005).
   PubMed Web of Science ®Google Scholar
• Womack KB, Heilman KM. Tolterodine and memory: dry but forgetful. Arch. Neurol.60, 771–773 (2003).
   PubMed Web of Science ®Google Scholar
• Tsao JW, Heilamn KM. Transient memory impairment and hallucinations associated with tolterodine use. N. Engl. J. Med.349, 2274–2275 (2003).
   PubMed Web of Science ®Google Scholar
• Juss JK, Radhamma AKJ, Forsyth DR. Tolterodine-induced hyponatremia. Age Aging34, 524–525 (2005).
   Google Scholar
• Garely AD, Burrows L. Benefit–risk assessment of tolterodine in the treatment of overactive bladder in adults. Drug Saf.27, 1043–1057 (2004).
   PubMed Web of Science ®Google Scholar
• Kim YT, Kwon DD, Kim J, Kim DK, Lee JY, Chancellor MB. Gabapentin for overactive bladder and nocturia after anticholinergic failure. Int. Braz. J. Urol.30(4), 275–278 (2004).
   PubMedGoogle Scholar
• Fry CH, Ikeda Y, Harvey R, Wu C, Sui GP. Control of bladder function by peripheral nerves: avenues for novel drug targets. Urology63, 24–31 (2004).
   PubMed Web of Science ®Google Scholar